Nola M. Hylton - Concepedia

Author

Nola M. Hylton

University of California, San Francisco ORCID

Also Known As

A DeMichele, Alfred Au, Amy Clark, Angela DeMichele, Angela Demichele, Daniel F. Hayes, Esserman, Laura J., Hudis, Clifford A., Hylton, Nola, Hylton, Nola M.

377

Publications

14.2K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco University of Pennsylvania The University of Texas MD Anderson Cancer Center University of Chicago University of Washington

About

Nola M. Hylton is an author at University of California, San Francisco specializing in radiology, medicine, and medical imaging.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	31	2.1K
2	Engineering	18	26	1K
3	Health Sciences	17	26	1.6K
4	Biomedical Engineering	7	7	428
5	Public Health	1	1	29

Nola M. Hylton

148

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer Rita Nanda, Minetta C. Liu, Christina Yau, JAMA Oncology	2020	672
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele, New England Journal of Medicine	2016	543
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL Nola M. Hylton, Jeffrey D. Blume, Wanda K. Bernreuter, Radiology	2012	479
Adaptive Randomization of Neratinib in Early Breast Cancer John W. Park, Minetta C. Liu, Douglas Yee, New England Journal of Medicine	2016	453
Utility of Magnetic Resonance Imaging in the Management of Breast Cancer: Evidence for Improved Preoperative Staging Laura J. Esserman, Nola M. Hylton, Leila Yassa, Journal of Clinical Oncology	1999	382
Accuracy of MR Imaging for Revealing Residual Breast Cancer in Patients Who Have Undergone Neoadjuvant Chemotherapy Savannah C. Partridge, Jessica Gibbs, Ying Lü, American Journal of Roentgenology	2002	339
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial Lajos Pusztai, Christina Yau, Denise M. Wolf, Cancer Cell I-spy2 TrialBreast OncologyMedicinePharmacologyImmune Checkpoint Inhibitor	2021	300
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Cancer Cell	2022	294
MRI Measurements of Breast Tumor Volume Predict Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival Savannah C. Partridge, Jessica Gibbs, Ying Lü, American Journal of Roentgenology	2005	274
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial Savannah C. Partridge, Zheng Zhang, David C. Newitt, Radiology Breast OncologyNeoadjuvant ChemotherapyMedical ImagingOncologic ImagingMedicine	2018	274

Page 1